A potential new treatment for ulcerative colitis (ATLAS-UC)
This trial is testing MK-7240 in people with moderately to severely active ulcerative colitis (UC).
MK-7240 is experimental. It has not been approved in Australia.
This trial will compare MK-7240 to placebo. A placebo looks like a trial drug, but it has no active ingredients.
This trial is being done to:
• Test the safety of MK-7240
• See how well MK-7240 works, compared to placebo
MK-7240 is a monoclonal antibody (man-made antibodies that act like human antibodies in the immune system) that may reduce inflammation and
fibrosis (scar tissue) associated with inflammatory bowel disease, such as UC and Crohn’s disease.
What you need to know
Who can take part?
To participate you must:
Be aged between 16 & 75
Have moderately to severely active UC
Weigh at least 40kg
Meet the prior treatment inclusion criteria
Not be pregnant or planning pregnancy
Not have any other bowel condition
Not have received a fecal transplant in the 4 weeks prior to study entry
Not have an current or recent infection
Not have a history of malignancy
Certain medication may make you ineligible to participate
What is involved for me?
Medical history and collection of demographic information
Vital signs
Electrocardiogram
Physical exam
Blood and urine tests
Pregnancy tests for women with childbearing potential
Colonoscopy with tissue biopsy
Daily diary completion
Questionnaires
Regular study visits
Treatment by IV infusion then later on by subcutaneous injection
